Research Overview

Jennifer M. Yeh, PhD, is a decision scientist whose research focuses on improving health outcomes at the population level. She has extensive experience applying decision-analytic modeling and cost-effectiveness analysis methods to evaluate clinical guidelines and health policy. Her research focuses primarily on cancer control and spans across the cancer continuum, ranging from gastric cancer prevention to childhood cancer survivorship. Dr. Yeh has developed and applied methods of decision analysis, simulation modeling and economic evaluation to identify opportunities to enhance cancer screening and surveillance programs. In particular, she has developed novel approaches that incorporate the effects of early life exposures on long-term health outcomes. Her work on childhood cancer survivorship focuses on how treatment-related risks for secondary cancers, cardiac events and other late effects impact long-term health and quality of life. She was recently awarded a grant from the American Cancer Society to evaluate secondary cancer screening guidelines for childhood cancer survivors.

 

Research Background

Dr. Yeh is an Assistant Professor of Pediatrics at Harvard Medical School and Associate Scientific Researcher in the Division of General Pediatrics at Boston Children's Hospital. She graduated from the University of Colorado at Boulder with a B.A. in Biology, received an M.S. in Health Policy and Management from the Harvard T.H. Chan School of Public Health, and completed her doctorate from the Health Policy PhD program at Harvard University, concentrating in Decision Sciences. Upon completing a NCI-sponsored post-doctoral fellowship at the Harvard T.H. Chan School of Public Health and Dana Farber/Harvard Cancer Center, she was awarded a NCI K07 Career Development Award. She is a current recipient of an American Cancer Society Research Scholar Grant.

Publications

  1. Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2024 Oct 01. View Abstract
  2. The Association of Race, Ethnicity, and Insurance Status with the Visual Acuity of Retinoblastoma Survivors in the IRIS® Registry. Ophthalmic Epidemiol. 2024 Apr 05; 1-7. View Abstract
  3. Prevalence of Gastric Precursor Lesions in Countries With Differential Gastric Cancer Burden: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2024 Aug; 22(8):1605-1617.e46. View Abstract
  4. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program. J Natl Cancer Inst Monogr. 2023 11 08; 2023(62):219-230. View Abstract
  5. Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: Estimates from the PreEMPT model. Genet Med. 2023 04; 25(4):100797. View Abstract
  6. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023 02 01; 41(4):859-870. View Abstract
  7. Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis. Lancet Diabetes Endocrinol. 2022 12; 10(12):848-858. View Abstract
  8. Variation in the incidence of type 1 diabetes mellitus in children and adolescents by world region and country income group: A scoping review. PLOS Glob Public Health. 2022; 2(11):e0001099. View Abstract
  9. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. J Natl Cancer Inst. 2022 05 09; 114(5):722-731. View Abstract
  10. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol. 2022 04 01; 8(4):587-596. View Abstract
  11. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. J Natl Cancer Inst. 2022 02 07; 114(2):235-244. View Abstract
  12. The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review. Front Endocrinol (Lausanne). 2022; 13:815703. View Abstract
  13. Incidence and prevalence of type 1 diabetes and diabetic ketoacidosis in children and adolescents (0-19 years) in Thailand (2015-2020): A nationwide population-based study. Lancet Reg Health West Pac. 2022 Apr; 21:100392. View Abstract
  14. Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. Med Decis Making. 2022 02; 42(2):194-207. View Abstract
  15. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 10 01; 4(10):e2129742. View Abstract
  16. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genet Med. 2021 07; 23(7):1366-1371. View Abstract
  17. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021 Mar-Apr; 50-51:101735. View Abstract
  18. The Modest Effects of Fact Boxes on Cancer Screening. J Risk Uncertain. 2021 Feb; 62(1):29-54. View Abstract
  19. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2020 11 20; 38(33):3851-3862. View Abstract
  20. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Ann Intern Med. 2020 09 01; 173(5):331-341. View Abstract
  21. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020 04; 21(4):e185-e224. View Abstract
  22. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol. 2020 03 01; 6(3):350-357. View Abstract
  23. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019 07; 20(7):972-983. View Abstract
  24. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019 04; 20(4):483-493. View Abstract
  25. New Agents, Emerging Late Effects, and the Development of Precision Survivorship. J Clin Oncol. 2018 07 20; 36(21):2231-2240. View Abstract
  26. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553. View Abstract
  27. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol. 2017 Aug; 112(8):1256-1264. View Abstract
  28. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer. 2017 Sep; 20(5):811-824. View Abstract
  29. Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst. 2016 09; 108(9). View Abstract
  30. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2016 Apr; 65(4):563-74. View Abstract
  31. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014 May 20; 160(10):661-71. View Abstract
  32. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013; 10(5):e1001451. View Abstract
  33. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics. 2013 Apr; 131(4):e1135-43. View Abstract
  34. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. Blood. 2012 Sep 13; 120(11):2195-202. View Abstract
  35. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer. 2010 Jun 15; 116(12):2941-53. View Abstract
  36. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc. 2010 Jul; 72(1):33-43. View Abstract
  37. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010 Apr 06; 152(7):409-17, W131-8. View Abstract
  38. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS One. 2010 Mar 01; 5(3):e9483. View Abstract
  39. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control. 2009 Dec; 20(10):2021-9. View Abstract
  40. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009 Jan 01; 124(1):157-66. View Abstract
  41. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1179-87. View Abstract
  42. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis. 2003 May; 30(5):369-78. View Abstract

Contact Jennifer Yeh

Print Profile